Does metformin reduce vitamin B12 absorption and lower B12 status?

Metformin therapy is the cornerstone of type 2 diabetes management, but long-term administration is clinically linked to altered vitamin B12 status and its downstream metabolic biomarkers.

Clinical evidence and biomarkers

• Large-scale cohort analyses, such as the Diabetes Prevention Program Outcomes Study (DPPOS), demonstrate a clear dose- and duration-dependent relationship between metformin use and lower serum vitamin B12 levels.
• This decline in B12 status impairs cobalamin-dependent enzymatic reactions, resulting in the systemic accumulation of homocysteine and methylmalonic acid (MMA).
• Elevated MMA and homocysteine serve as highly sensitive biomarkers of functional, tissue-level B12 deficiency, and their metabolic accumulation clinically correlates with exacerbated peripheral neuropathy and increased cardiovascular risk markers.

Mechanistic explanations

• Metformin, a cationic biguanide, accumulates at the brush border membrane of the terminal ileum where its positive charge alters the local membrane surface charge.
• This alteration repels divalent calcium cations, creating a localized calcium deficit that disrupts the calcium-dependent binding of the intrinsic factor–B12 (IF-B12) complex to the cubilin/cubam receptor.
• This membrane-level antagonism directly blocks receptor-mediated endocytosis of B12, though oral calcium supplementation can reverse this malabsorption by restoring calcium availability at the receptor site.

Bottom line

• Metformin directly impairs vitamin B12 absorption through a reversible, calcium-dependent receptor interaction in the ileum, leading to reduced serum B12 levels and functional tissue-level deficiency marked by elevated homocysteine and MMA.